Please login to the form below

Not currently logged in


This page shows the latest free-spending news and features for those working in and with pharma, biotech and healthcare.

A frugal future

A frugal future

more. But that environment is changing. Free-spending, arguably profligate life science companies will die out and frugal, ruthlessly efficient companies will replace them. ... Free-spending, arguably profligate life science companies will die out and

Latest news

  • Life sciences minister: Go digital for NHS savings Life sciences minister: Go digital for NHS savings

    Greater use of health technology could free funds for drug spending, says George Freeman.

  • GSK accused of intimidation

    GSK also lobbied on the Medicare prescription drug programme, legislation which proposes an expansion of child healthcare, government spending on health programmes and several free trade agreements, according to the form

  • News in brief, April 25, 2007

    The 33 countries also included three candidate countries: Croatia, Macedonia, Turkey and the European Free Trade Area (EFTA) nations Iceland, Norway and Switzerland. ... Pharmaceutical firms say that if the legislation went ahead, it would impact their

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....